Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio) Phase II Trial
SEOUL, South Korea, May 19, 2023. Genome & Company a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis.
Using a single-strain bacteria in combination with avelumab (Bavencio) from Merck KGaA, Darmstadt, Germany and Pfizer Inc., it is the first time to show positive antitumor activity per objective response rate (ORR) in Phase II trial.
On the basis of these results and in accordance with the predetermined hypothesis of the interim analysis, Genome & Company highly expect that the evidence for treatment with GEN-001 plus avelumab as a 3rd line of therapy for gastric or gastroesophageal junction cancer (GC/GEJ) will be strongly established.
This is a Phase II study to evaluate the safety and efficacy of GEN-001 plus Avelumab as a ≥3rd line treatment for PD-L1 positive GC/GEJ patients regardless of prior immune-oncology treatment. Following enrollment of the 21st patient, a pre-planned interim analysis was conducted and results were reviewed by an independent data monitoring committee.
As the observed ORR met the pre-determined criteria together with no safety concerns, the IDMC recommended to continue with the second stage without modifications and enroll additional 21 patients. The detailed results will be presented at an Oncology conference in the second half of 2023. The top-line data of the final analysis from Phase II are expected in the second half of next year.
Professor Jeeyun Lee, the principal investigator of clinical trials from the Hematology and Oncology Division at Samsung Medical Center, stated, "There is a strong unmet medical need to establish 3rd line of therapy for GC/GEJ patients compared with the establishing 1st and 2nd lines of therapy. Hence, the pre-planned interim result of this trial is quite interesting. We continue to enroll patients and look forward to seeing the final analysis of this trial soon."
The CEO of Genome & Company, Pae, Jisoo, stated, "We attach great significance to presenting data-driven results for the first time through Phase II clinical trials on gastric cancer patients using the immuno-oncology microbiome therapeutic 'GEN-001' in combination with avelumab from Merck KGaA, Darmstadt, Germany and Pfizer Inc." and "we intend to obtain phase II clinical data for 'GEN-001' within next year and to discuss a licensing agreement with partners or global big pharmaceutical companies."
SOURCE Genome & Company
Posted: May 2023
Related articles
- FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma - June 30, 2020
- FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma - May 14, 2019
- FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma - May 9, 2017
- FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma - March 23, 2017
- FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review - February 28, 2017
- FDA Accepts the BLA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review - November 29, 2016
Bavencio (avelumab) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
